---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-154245"
form_type: "8-K"
ticker: "QNCX"
cik: "0001662774"
company_name: "Quince Therapeutics, Inc."
filed_at: "2023-05-25T23:59:59+00:00"
generated_at: "2026-06-14T14:39:14.370069+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Quince Therapeutics shareholders approve 1-for-10 reverse stock split and elect directors at annual meeting

## Summary
- Shareholders approved 1-for-10 reverse stock split: 22.3M votes for, 4.0M against.
- Margaret McLoughlin and Una Ryan elected as Class I directors with over 8.1M votes each.
- Ratification of BDO USA as auditor for FY2023 approved with 22.9M votes for.
- Advisory vote on executive compensation passed with 8.7M votes for, 2.3M against.

## SEC filing metadata
- accession: 0001193125-23-154245
- form_type: 8-K
- ticker: QNCX
- cik: 0001662774
- company_name: Quince Therapeutics, Inc.
- filed_at: 2023-05-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662774/000119312523154245/0001193125-23-154245-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662774/000119312523154245/d367319d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-154245
- JSON: https://secwatch.observer/filing/0001193125-23-154245.json
- Plain text: https://secwatch.observer/filing/0001193125-23-154245.txt

## Key facts
- Shareholder Votes
  Quince Therapeutics, Inc. shareholders approved Election of two Class I directors at the 2023-05-24 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-05-24
  source text: The Company’s stockholders approved the election of two Class I directors to the Board of Directors for three year terms or until their respective successors are duly elected and qualified or until their earlier death, resignation, disqualification or removal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312523154245/0001193125-23-154245-index.htm
- Shareholder Votes
  Quince Therapeutics, Inc. shareholders approved Ratification of Selection of Independent Registered Accounting Firm BDO USA, LLP at the 2023-05-24 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-05-24
  source text: The Company’s stockholders ratified the selection of BDO USA, LLP as the Company’s independent registered accounting firm for the fiscal year ending December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312523154245/0001193125-23-154245-index.htm
- Shareholder Votes
  Quince Therapeutics, Inc. shareholders approved Advisory approval of the compensation of the Company's named executive officers at the 2023-05-24 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-05-24
  source text: The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312523154245/0001193125-23-154245-index.htm
- Shareholder Votes
  Quince Therapeutics, Inc. shareholders approved Approval of Amendment to the Certificate of Incorporation to Effect a Reverse Stock Split at a ratio of one-for-ten at the 2023-05-24 meeting.
  - Proposal: reverse split
  - Outcome: passed
  - Meeting: 2023-05-24
  source text: The Company’s stockholders approved the amendment to the Company’s amended and restated certificate of incorporation to effect a reverse stock split of the issued and outstanding common stock at a ratio of one-for-ten.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312523154245/0001193125-23-154245-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.